Denmark’s entry point to advanced therapies
We work to establish a single, coordinated gateway to ATMP in Denmark, so that Danish patients can gain early access to new treatments.
Towards a sustainable organization of ATMP Denmark
ATMP Denmark traces its origins to the government’s Life Science strategy and was established by The Danish Ministry of Health and the Church, Danish Regions, and Amgros. The secretariat is anchored in Amgros.
The secretariat coordinates the work, while the steering committee sets the strategic direction. The reference group ensures anchoring in clinical practice and research.
ATMP Denmark is organized as a program from 2024 to 2027, focusing on developing and establishing a single common gateway to the ATMP field in Denmark. The goal is to point to a sustainable organization of ATMP Denmark after 2027.
Denmark in numbers
Denmark ranks number three in Europe for the speed from the Danish Medicines Council’s recommendation to treatment at hospitals.
ATMPs are recommended by the Danish Medicines Council for 13 different patient groups in Denmark.
6.7 clinical trials per million inhabitants. Denmark ranks second in Europe in clinical trials within advanced therapies.
Together we build health
From collaboration and advisory services to analysis and networking—our efforts are divided into four tracks that bring new treatments closer to patients.
Cancer treatment paves the way for new therapies
CAR-T therapy is already used for selected forms of blood cancer. The treatment involves changing the patient’s own immune cells so that they can better recognize and attack diseased cells.
Now researchers are investigating whether the technology can also be used for selected, difficult autoimmune diseases such as systemic lupus and multiple sclerosis. In autoimmune diseases, the immune system attacks the body’s own cells, and therefore a targeted treatment of the immune system may be relevant for some patients.
Research is also underway into whether CAR-T can be used for other diseases in which the immune system plays an important role, and whether the treatment in the long term can be expanded to other types of cancer beyond blood cancer.
Commercial CAR-T treatment is provided to Danish patients in clinical trials or as standard treatment. Currently, treatments take place here: | Academic development and research in CAR-T treatment primarily takes place here: | ||
|
|
Many stakeholders contribute to the work of ATMP Denmark
AMTP Denmark collaborates broadly with both regions, universities, the pharmaceutical industry, and relevant authorities. We have organized the collaboration so that it consists of a steering committee, a reference group, a secretariat, and working groups.
In addition to setting the strategic direction, the steering committee also formulates objectives and decides whether analyses and pilot projects should be initiated. The group helps ensure progress in the activities that have been launched and supports collaboration within the ATMP area.
Three types
ATMP stands for Advanced Therapy Medicinal Products and is also referred to as advanced therapies. These are medicines based on genes, cells, or tissue that can repair, replace, or modify biological functions in the body.
Regulatory support
We offer regulatory guidance that can help researchers and clinicians, as well as companies, create an overview of the regulatory requirements in connection with the development and implementation of ATMP products. In addition, we establish and run national regulatory networks intended to promote knowledge sharing, dialogue, and a shared understanding of the requirements for the development and clinical testing of ATMPs.
Write to us - we’ll get back to you
We handle all inquiries confidentially. Send us an email and briefly tell us what you would like to clarify, and we will arrange the next step.
